Ganstingmine Chiesi

Current Opinion in Investigational Drugs

Volumn 4, Issue 7, 2003, Pages 868-873

  Johnson, Anthony ^a  

^a Anthony Johnson Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHF 2060; CHF 2822; CHF 2957; CHF 3360; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; ESERIDINE; ESERIDINE DERIVATIVE; GALANTAMINE; GANSTIGMINE; METRIFONATE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR AGONIST; PHENSERINE; PHENYLGENESERINE; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; SCOPOLAMINE BROMIDE; SEROTONIN; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANOREXIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; INHIBITION KINETICS; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; NAUSEA; NEUROTRANSMITTER RELEASE; NONHUMAN; PHARMACODYNAMICS; REVIEW; SALIVATION DISORDER; SENILE DEMENTIA; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICITY; TREATMENT OUTCOME; VOMITING;

EID: 0142094603     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. 259785 Chiesi's Italian sales up 12%. Scrip World Pharmaceutical News 1997 11 2259
2. 261891 Drug development pipeline: CHF-2060, CHF-2819. Chiesi Pharmaceuticals Company Communication 1997 September 08
3. 344441 Annual report 1999 - Chiesi Pharmaceutici SpA. Chiesi Pharmaceutici SpA Annual Report 1999 October
4. 345920 Cholinesterase inhibitory activity and antiamnesic effect of CHF-2819, a potential antidementia drug. Villetti G, Battipaglia L, Bolzoni PT, Pietra C Abstr Soc Neurosci 1999 25 2 Abs 847.1
5. 359841 Research & Development. Chiesi Farmaceutici SpA Company World Wide Web Site 2000 March 16
6. 371281 Drug development pipeline: CHF-2819. Chiesi Pharmaceuticals Company Communication 2000 June 17
7. 397605 Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. Trabace L, Cassano T, Steardo L, Pietra C, Villetti G, Kendrick KM, Cuomo V J Pharmacol Exp Ther 2000 294 1 187-194 Principal report of the in vivo preclinical pharmacology of ganstigmine.
8. 428215 Acetylcholinesterase inhibitors in Alzheimer's therapy beyond classical pharmacology. Abstr Soc Neurosci 2001 27 2 Abs 549.6
9. 460036 News from the 8th International Conference on Alzheimer's Disease: Ganstigmine a new acetylcholinesterase inhibitor. Chiesi Pharmaceuticals Press Release 2002 July 20
10. 463437 Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. Yu QS, Zhu X, Holloway HW, Whittaker NF, Brossi A, Greig NH J Med Chem 2002 45 17 3684-3691
11. 470258 Muscarinic agonists as preventative therapy in Alzheimer's disease. Beach T Curr Opin Investig Drugs 2002 3 11 1633-1636 Overview of muscarinic cholinergic influences on APP and β-amyloid metabolism.
12. 473304 CHF2819: Pharmacological profile of a novel acetylcholinesterase inhibitor. Trabase L, Cassano T, Loverre A, Steardo L, Cuomo V CNS Drug Rev 2002 8 1 53-69
13. 473305 Phase I metabolism of ganstigmine. Rat, dog, monkey and human liver microsomal extracts investigated by liquid chromatography electrospray tandem mass spectrometry. Catinella S, Pelizzi N, Puccini P, Marchetti S, Zanol M, Acerbi D, Ventura P J Mass Spectrom 2001 36 12 1287-1293
14. 473306 Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. Trabace L, Cassano T, Cagiano R, Tattoli M, Pietra C, Steardo L, Kendrick KM, Cuomo V Brain Res 2001 910 1-2 182-186
15. 473314 Tolerability and pharmacodynamic effects of single doses of ganstigmine, a new cholinesterase inhibitor, in healthy men. Warrington S, Johnson N, Cattoni M, Boyce M Br J Clin Pharmacol 2000 49 5 503-504 First report of effects of ganstigmine in humans.
16. 476952 Selective loss of central cholinergic neurons in Alzheimer's disease. Davies P, Maloney AJ Lancet 1976 2 8000 1403 Initial report linking cholinergic neuron loss to Alzheimer's disease.
17. 476955 Rationalising a pharmacological intervention on the amyloid precursor protein metabolism. Racchi M, Govoni S Trends Pharmacol Sci 1999 20 10 418-423 An overview of the pharmacology of β-amyloid metabolism.
18. 476956 The effect of the cholinesterase inhibitors CHF 2060 and CHF 2819 on the amyloid precursor protein synthesis and metabolism. Racchi M, Mazzucchalli M, Govoni S Neurobiol Aging 2002 23 S1 304
19. 476957 Selective inhibitors of butyrylcholinesterase: A valid alternative for therapy of Alzheimer's disease? Giacobini E Drugs Aging 2001 18 12 891-898 Review assessing the rationale for the use of BChE inhibitors in Alzheimer's disease.
20. 476958 A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK Curr Med Res Opin 2001 17 3 159-165 Review assessing the rationale for the use of BChE inhibitors in Alzheimer's disease.
21. 476959 Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Ballard CG Eur Neurol 2002 47 1 64-70 Review assessing the rationale for the use of BChE inhibitors in Alzheimer's disease.
22. 476960 Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Mori F, Lai CC, Fusi F, Giacobini E Neuroreport 1995 6 4 633-636 First report of the effect of ChE inhibitors on APP metabolism.
23. 476961 Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH Acta Neurol Scand Suppl 2000 176 60-67 Overview of the effect of ChE inhibitors of APP and β-amyloid metabolism.
24. 476964 Pietra C, Villetti G, Bolzoni P, Delcanale M, Amari G, Caruso P, Civelli M: Cholinesterase inhibitory activity of new geneserine derivatives. In: Alzheimer's Disease and Related Disorders Iqbal K, Swaab DF, Winblad B, Wisniewski HM (Eds), John Wiley & Sons Ltd, Chichester, UK Initial report of the pharmacology of ganstigmine. 1999 689-696 Initial report of the pharmacology of ganstigmine.
25. 490742 The protective effect of ganstigmine against amyloid β 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition. Windisch M, Hutter Paier B, Jerkovic L, Imbimbo B, Villetti G Neurosci Lett 2003 341 3 181-184
26. 494292 First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease. Jhee SS, Fabbri L, Fabbri L, Piccinno A, Monici P, Moran S, Zarotsky V, Tan EY, Frackiewicz EJ, Shiovitz T Clin Neuropharmacol 2003 26 3 164-169